A class action lawsuit filed Monday in New Jersey federal court accuses ADMA Biologics of running a de facto channel stuffing scheme. The complaint, brought by the law firm Bleichmar Fonti & Auld LLP, alleges the company and senior executives violated federal securities laws. The case is Mazzarino v.
ADMA Biologics, Inc., et al., No. 26-cv-6918. Channel stuffing is a recognized red flag in business.
It means a company ships more product to distributors than end customers actually want. Revenue gets booked early. The pipeline fills.
Demand looks healthy on paper. It is not.
The complaint claims ADMA did exactly this with its flagship product, ASCENIV, to drive revenue growth when demand for the drug was waning. ASCENIV is a liquid immune globulin solution. It treats Primary Humoral Immunodeficiency in adults and adolescents.
ADMA Biologics is an end-to-end commercial biopharmaceutical company. It manufactures, markets, and develops specialty biologics. Those are the facts of the business.
The stock dropped. The drop was significant.
It was significant enough to trigger a securities fraud action. That is all the court filing says about the decline. No exact percentage.
No precise dollar loss. The law firm does not spell out the size of the fall.
What is known: the drop followed the alleged violations. Investors have a deadline. August 10, 2026.
That is the last day to ask the U.S. District Court for the District of New Jersey to appoint an investor as lead plaintiff in the case. The class action covers anyone who bought ADMA securities during the relevant period. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
Section 10(b) is the main antifraud provision. Section 20(a) deals with control-person liability.
Bleichmar Fonti & Auld is urging investors to contact them. The firm has a website with additional information. It is a standard move in securities class actions.
Lawyers look for the biggest investor to serve as lead. That investor gets more say in the litigation.
The lawsuit does not name the specific executives. It says “certain senior executives.” It does not name the exact dates of the alleged scheme. It does not say how much product was stuffed into the channel.
The details will come in discovery, if the case proceeds. ADMA Biologics has not yet filed a response in court. Companies typically deny allegations in securities fraud cases.
They often move to dismiss. The court will decide whether the complaint states a valid claim.
This is not a small firm. Bleichmar Fonti & Auld has handled major securities cases. They know the law.
They know the deadlines. They are telling investors to act by August 10, 2026.
The case is in New Jersey. That is where ADMA is headquartered. The judge assigned will oversee the lead-plaintiff process first.
Then comes the motion to dismiss. Then discovery, if the case survives. Investors should read the complaint.
It is a public document. It lays out the allegations.
Channel stuffing. Waning demand. Revenue growth that was not real.
A stock that dropped hard. That is the case.
That is the deadline. That is what happened.
